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Given the importance of dendritic cells in the immune response, we investigated the effect of corticosteroids (CS)
on the integrity, survival, and function of murine Langerhans cells (LC) in comparison with pimecrolimus, a novel
anti-inﬂammatory drug for the topical treatment of atopic dermatitis. BALB/c mice were treated twice on one day
with ethanolic solutions of the compounds. At 24–72 h after the last application, we observed fragmented DNA,
caspase-3 activity, and an upregulation of CD95 expression in LC from mice treated with CS but not in LC of
pimecrolimus- or vehicle-treated animals. CS-epidermal cell (EC) supernatants but not pimecrolimus-EC super-
natants contained signiﬁcantly lower amounts of soluble factors (GM-CSF, TNF-a, IL-1a) required for LC survival
and maturation than EC supernatants from vehicle-treated mice. With regard to LC maturation, CS but not
pimecrolimus inhibited the expression of CD25, CD205, and costimulatory molecules. In line with this, LC from
pimecrolimus-treated mice were similar to LC from vehicle-treated mice in their capacity to stimulate antigen-
presenting function and migration, whereas LC from CS-treated mice were greatly impaired in these abilities. In
summary, our data show for the ﬁrst time that CS but not pimecrolimus induce apoptosis in LC in situ, implying that
the prolonged use of CS could have adverse effects on the skin immune system.
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Corticosteroids (CS) are potent immunomodulatory hor-
mones, which are widely applied in the clinic for their
immunosuppressive properties. Their effect is mediated by
the cytosolic glucocorticoid receptor which, upon ligand
binding, translocates into the nucleus and regulates gene
expression (Danielsen et al, 1987; Hollenberg et al, 1987).
Most cells of the immune system are adversely affected by
CS (e.g., T cells, B cells, natural killer cells, macrophages/
monocytes, and dendritic cells (DC)) (Schwartzman and
Cidlowski, 1994; Moser et al, 1995; Schmidt et al, 1999). In
the epidermis, the main targets of CS are thought to be
basal keratinocytes and Langerhans cells (LC). This
assumption is supported by the fact that human basal
keratinocytes and LC strongly express the glucocorticoid
receptor (Serres et al, 1996). With regard to LC, a decrease
of MHC class IIþ epidermal LC after topical treatment with
CS has been observed by several investigators, but the
mechanism underlying this phenomenon has not yet been
elucidated.
For short treatment periods, oral and topical formulations
of CS are usually well tolerated, while long-term application
is limited by local and systemic side-effects (e.g., skin
atrophy, growth retardation, etc.) (Stoppolino et al, 1983). As
a consequence, many efforts have been made to develop
therapeutic alternatives. Recently, a promising class of anti-
inflammatory substances (e.g., pimecrolimus (SDZ ASM
981, Elidel), tacrolimus (FK 506, Protopic)) has been
identified for the treatment of inflammatory skin diseases
(Ruzicka et al, 1997; Van Leent et al, 1998; Luger et al,
2001). Unlike CS, these compounds have no atrophogenic
potential (Meingassner et al, 1997; Reitamo et al, 1998;
Queille-Roussel et al, 2001). Pimecrolimus and tacrolimus
have a similar mode of action, which is mediated mainly by
specific intracellular ligands, the immunophilins, among
which macrophilin-12 binds to both compounds. The
macrophilin-12 complex inhibits calcineurin and causes a
downregulation of important T cell-derived cytokines (e.g.,
IL-2, IL-4, IL-5) (reviewed in Nghiem et al, 2002) (Grass-
berger et al, 1999).
While one can safely assume that pimecrolimus mainly
acts at the level of T cells, other immunocompetent cells in
the skin could also be relevant targets. Because the exact
mode of action in the skin is not known for CS or
pimecrolimus, we explored in detail the effects of CS onPlace of work: Vienna, Austria.
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the immune functions of resident skin cells with special
emphasis on LC in vivo, and compared these effects with
those of pimecrolimus. We found that topical CS induce
apoptosis of LC in vivo and greatly impair the maturation
and antigen-presenting function of LC. In contrast, topical
application of pimecrolimus did not affect viability, matura-
tion and migration, and had no gross effects on immune
functions of LC.
Results
Murine LC and keratinocytes express macrophilin-12 As
shown in Fig 1A and B, murine LC and keratinocytes exhibit
anti-macrophilin-12 reactivity. Only a subpopulation of LC
was strongly macrophilin-12 positive, whereas others
expressed only moderate levels or were negative, suggest-
ing that the epidermis contains LC with a different
differentiation status. When epidermal cells (EC) were kept
in culture however, macrophilin-12 expression was highly
upregulated on all LC (Fig 1C). This is in contrast to findings
in human LC, where macrophilin-12 expression disappears
during maturation (Panhans-Gross et al, 2001). The reason
for this discrepancy is currently unclear. To investigate
whether topically applied pimecrolimus alters macrophilin-
12 expression in LC, EC suspensions were prepared at
selected time points after treatment, permeabilized, stained
with anti-MHC class II and anti-macrophilin-12, and ana-
lyzed by flow cytometry. After 24 h, macrophilin-12 staining
in LC was reduced by *60% (Fig 2), implying that
pimecrolimus binds to macrophilin-12 in LC.
Pimecrolimus is a potent inhibitor of the elicitation
phase of CHS The pharmacodynamic effect of pimecroli-
mus under our present treatment conditions was tested in a
CHS model. In two independent experiments we found that
1% pimecrolimus, applied twice on 1 d, inhibited inflam-
matory ear swelling by 40% (Table I).
Topical CS but not pimecrolimus application induces
apoptosis in LC Contact hypersensitivity (CS) exert their
biological activity by binding to their receptor (Reichardt
et al, 2000). FACS analysis revealed that approximately
a quarter of the freshly isolated LC population strongly
expresses the receptor (Fig 3A, left panel), suggesting that
LC are heterogeneous in terms of sensitivity to CS.
Furthermore, we found that one-third of MHC class II EC,
presumably keratinocytes, express the glucocorticoid re-
ceptor (Fig 3A, right panel). To determine the effects of
pimecrolimus and CS on the fate and phenotype of EC,
single-cell suspensions from treated mice were prepared
and analyzed at selected time points. While the percentage
of dead EC was essentially equal in vehicle (5%)- and
pimecrolimus (6%)-treated skin areas, the percentage of
dead EC was significantly increased (po0.001) up to 13%
and 14% in hydrocostisone (HC) and clobetasol propionate
(CL)-treated mice, respectively. As shown in Fig 3B, neither
CS nor pimecrolimus had changed the numbers and MHC
class II expression levels of LC when assessed at and
compared with controls 24 h after cessation of treatment.
Two days later, however, treatment with CS but not with
pimecrolimus had resulted in a decrease of MHC class IIþ ,
CD24þ , CD32þ , CD11bþ , and F4/80þ cells (Fig 3B, supp-
lementary data (Fig S3C) online). Furthermore, mean
fluorescence intensity (MFI) of surface MHC class II
molecules of LC was reduced (Fig 3B), while the expression
intensity of the other markers was not affected on the
remaining cells. Effects on LC phenotype were also not seen
when mice were treated with pimecrolimus twice/day for 5
consecutive days (supplementary data (Fig S3D, E) online).
To determine whether the CS-induced numerical reduction
of LC is attributable to an altered migration pattern of LC, we
used the skin explant culture model described by Larsen
et al (1990). Figure 4A shows that after 72 h of organ culture
CD74þ LC in the epidermis of CL-treated mice were
decreased compared to controls. A dramatic reduction of
cords and cells within these cords in CL-treated dermis
Figure1
Murine EC express macrophilin-12. (A) Epidermal sheets were
exposed to FITC-anti-macrophilin-12/PE-anti-MHC II double labeling
and analyzed with a confocal laser scanning microscope (CLM). MHC
class IIþ LC with high macrophilin-12 expression are indicated by an
arrow, and MHC class IIþ /macrophilin-12 LC by arrowheads. MHC
class II EC, presumably keratinocytes, express low levels of
macrophilin-12 (open arrows). (B) EC suspensions were double labeled
with FITC-anti-macrophilin-12/PE-anti-MHC II directly after isolation
and assessed by flow cytometry. Setting analytical gates for PE-MHC
class II-labeled cells, 104 cells were acquired (left histogram). The right
histogram shows macrophilin-12 staining in MHC class II EC. Dotted
lines in histograms represent isotype controls. (C) Kinetics of the
macrophilin-12 staining in LC upon culture. Results are representative
of three independent experiments. Scale bars: 20 mm.
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indicates that the decrease of LC observed in the epidermis
was not due to an altered migration pattern of LC (Fig 4A,
supplementary data (Fig S4) online). The few MHC class IIþ
cells within the cords were negative for maturation markers
(e.g., CD80 (CD86, CD40 see supplementary data Fig S4
online)). In line with this, the emigrated DC/LC in the CL-
treated group were highly diminished and showed a low
expression of MHC II and CD86 (Fig 4B, C). In contrast, LC
in epidermal/dermal sheets and emigrated DC/LC in control-
and pimecrolimus-treated skin were comparable in numbers
and maturation marker pattern (Fig 4A–C). To test whether
LC depletion is due to apoptosis, epidermal sheets were
double-stained with the (TUNEL) kit and an LC-specific
MoAb and examined with a CLM. Morphologically, LC in the
CS-treated groups became round in shape, with scanty or
no dendrites as compared with LC of the control mice. While
in the control- and pimecrolimus-treated epidermis 2%–3%
MHC class IIþ EC were TUNELþ , indicating the natural
turnover of LC, the percentage of apoptotic LC significantly
increased to 13% and 24% in the HC and CL group,
respectively (Fig 5A, B). In addition, TUNELþ /MHC class II
cells were also present in the CS-treated groups, most of
which were probably keratinocytes (Fig 5A). These findings
show that topically applied CS but not pimecrolimus induce
apoptosis in LC and keratinocytes in situ. Because caspase-
3 is a key effector caspase in various forms of apoptosis and
degrades several cellular proteins, we investigated its
involvement in CS-induced LC apoptosis. Indeed, CS- but
not pimecrolimus- or vehicle-treatment induced caspase-3
activity in LC (Fig 6A). Recent in vitro and in vivo studies
have suggested a susceptibility of LC to CD95/CD95L-
mediated apoptosis (Kawamura et al, 1999, 2000; Matsue et
al, 1999). Therefore, we tested a potential involvement of the
CD95 system in CS-induced apoptosis and determined CD95
and CD95L expression on LC and keratinocyte surfaces.
By FACS analysis of freshly isolated EC suspensions 24 h
after the last application of compounds, we observed an
upregulation of CD95 expression on MHC class IIþ LC
treated with CS but not on LC of pimecrolimus-treated mice
and controls (Fig 6B). In contrast, CD95L expression was
upregulated neither on MHC class IIþ nor on MHC class II
EC. In line with this, CS-induced LC apoptosis was not
reduced by a neutralizing CD95L monoclonal antibody
(MoAb) in vitro (data not shown). These results suggest that
CS induce LC death directly and may involve the CD95
pathway in a CD95L-independent fashion.
CS impair production of pro-inﬂammatory cytokines by
EC in contrast to pimecrolimus When testing whether the
topical application of CS and pimecrolimus alters the
secretion of certain keratinocyte-derived cytokines which
are critical for LC survival, we found that CS-EC super-
natants contained significantly lower amounts of GM-CSF,
TNF-a, and IL-1a than EC supernatants from vehicle-
treated mice (Fig 7). Surprisingly, pimecrolimus-EC super-
natants contained significantly higher levels of these
cytokines compared to controls. Concerning the role of
GM-CSF for LC survival, we found that the addition of GM-
CSF to EC suspensions prepared from CS-treated mice
greatly improved LC viability (Table II). These data show that
CS but not pimecrolimus lead to a downregulation of pro-
inflammatory cytokines in keratinocytes and, thus, may in
part deliver an initial pro-apoptotic signal for LC.
Pimecrolimus upregulates the endocytic capacity of
LC To investigate whether topical application of immuno-
modulating compounds influences the endocytic capacity
of LC, auricular and tail skin were treated with pimecroli-
mus, CS, or vehicle. Forty-eight hours after treatment, EC
suspensions were prepared, and FITC-ovalbumin (OVA)
uptake, mainly by fluid phase, by LC was analyzed. As
shown in Fig 8A, endocytic activity of LC isolated from CS-
treated mice was similar to controls. In contrast, antigen
capture was increased in LC treated with pimecrolimus. In
view of this finding, we evaluated the ability of LC to
process and present a soluble antigen upon topical
treatment with the compounds. Freshly isolated EC from
pimecrolimus-, CS- or vehicle-treated skin areas were
pulsed with hen egg lysozyme (HEL) for 24 h. Subsequently,
LC-enriched EC (adjusted to equal numbers of LC) were
cocultured with the HEL-specific, MHC class II-restricted
T cell hybridoma 1H11.3 for 24 h. Figure 8B shows that
Figure 2
Topical treatment with pimecrolimus alters macrophilin-12 expres-
sion in LC. Mice were treated topically with pimecrolimus, and 24 and
48 h later, macrophilin-12 expression in freshly isolated LC was
analyzed by flow cytometry as described in Fig 1. Dotted lines in
histograms represent isotype controls. Results are representative of
two independent experiments.
Table I. Pimecrolimus markedly inhibits CHS responsesa
Experiments Groups
Differences in
auricular weights
(mg) mean  SD
% inhibition
mean  SEM
I Pimecrolimus 14.8  4.5 39  8.4
Control 24.0  5.6 —
II Pimecrolimus 16.0  2.8 41  4.6
Control 26.9  2.8 —
aCHS in mice was elicited as described in Material and Methods. 0.5
and 8.5 h after challenge, mice (eight mice per group) were topically
treated with 1% pimecrolimus or vehicle alone. Anti-inflammatory activity
was calculated as the percentage inhibition of auricular weight increase
(as a measure of inflammation) relative to mice treated with vehicle alone.
po0.01 versus controls.
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LC-enriched EC from pimecrolimus-treated mice were
superior to LC-enriched EC from vehicle-treated mice in
their ability to stimulate T cells, as assessed by their IL-2
production. In contrast, LC-enriched EC from CS-treated
mice showed much lower efficiency in stimulating hybrido-
ma cells. To test whether the enhanced (pimecrolimus) or
decreased (CS) stimulation of hybridoma cells is due to
altered capacities of LC or to secondary effects (e.g., factors
secreted from keratinocytes), LC were highly enriched, and
the assay was performed as described. While LC from
pimecrolimus-treated mice presented antigen as effectively
as LC from vehicle-treated mice, LC from CS-treated mice
again were defective in presenting antigen (Fig 8C).
In contrast to pimecrolimus CS impair LC maturation
and hamper their stimulatory capacity To evaluate
whether topical application of pimecrolimus and CS has
any effects on the maturation and immune function of LC,
48 h EC suspension cultures from CS-, pimecrolimus-, or
vehicle-treated skin were tested for viability, phenotype, and
LC-dependent immune functions. While the viability of EC
prepared from pimecrolimus- and vehicle-treated skin areas
was greater than 70%, that of EC from HC- and CL-treated
mice was only 55% and 39% (n¼3), respectively. FACS
phenotyping, while revealing comparable levels of surface-
bound MHC class II molecules on LC from all groups,
showed a decreased expression of CD25, CD205, and the
costimulatory molecules CD40, CD54, CD80, CD86 on LC
derived from CS-treated animals compared to pimecroli-
mus- and vehicle-treated mice (Fig 9A). In line with this, LC-
enriched EC (adjusted to equal numbers of viable LC) from
pimecrolimus-treated mice induced a vigorous allogeneic T
cell response comparable to that evoked by LC-enriched
EC from vehicle-treated mice, with a peak occurring on
days 4 and 5 for CD8þ and CD4þ T cells, respectively
(Fig 9B). In contrast, LC-enriched EC from CS-treated mice
were greatly hampered in this capacity (Fig 9B). To study the
quality of the T cell response, CD4þ T cells, primed in the
MLR by LC-enriched EC from vehicle- or pimecrolimus-
treated mice, were expanded for 7 d and then restimulated
with irradiated antigen-presenting cells (APC). While the
analysis of cytokines revealed high levels of IFN-g in both
groups, there was a relative increase of IL-4 and IL-10 in the
pimecrolimus as compared to the vehicle group, indicating
that pimecrolimus-treated LC are able to skew a T cell
response into a TH2 direction (Fig 9C). Taken together, these
results show that, in contrast to CS, pimecrolimus does not
interfere with the maturation and immune function of LC and
those of other EC, although the quality of the T cell response
was slightly different.
Discussion
Besides the long-used CS, a new class of topical
immunomodulators—tacrolimus and pimecrolimus, also
termed calcineurin inhibitors—has recently been shown to
be effective in the treatment of eczematous skin diseases.
While CS and calcineurin inhibitors mediate their immuno-
suppressive function by affecting skin-infiltrating T cells,
mast cells, and basophils, their impact on APC in the
skin seems to be divergent. With regard to CS, several
investigators have shown a depletion of LC and an
impairment of their immune functions upon topical treat-
ment (Nordlund et al, 1981; Belsito et al, 1982, 1984a, b;
Berman et al, 1983; Aberer et al, 1984; Aberer et al, 1986;
Furue and Katz, 1989). The effect of calcineurin inhibitors
on LC is not so clear however. Tacrolimus affects the
phenotype and function of human LC in vitro, leading to a
downregulation of MHC I and II, CD25, CD40 and CD80
Figure 3
Epicutaneous treatment with CS
leads to a decrease in the number of
epidermal LC and a downregulation
of MHC class II expression in contrast
to pimecrolimus. (A) For the detection
of the glucocorticoid receptor, EC sus-
pensions of untreated skin were pre-
pared, fixed, permeabilized, and stained
as described in Materials and Methods.
Glucocorticoid receptor expression in
MHC class IIþ (left histogram) and MHC
class II (right histogram) EC was
evaluated by flow cytometry as de-
scribed in Fig 1. (B) Mice were treated
topically with pimecrolimus, CS, and
vehicle. After 24 and 48 h, EC were
prepared, stained with the indicated
MoAb, and analyzed by flow cytometry.
104 events per sample were acquired.
Dot plots represent the results of five
independent experiments.
676 HOETZENECKER ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Figure 4
Pimecrolimus has no effects on migration and maturation of LC in contrast to CS. BALB/c mice were treated twice on one day on both sides of
the ears with vehicle, pimecrolimus, and CL. Forty-eight hours after the last application, dorsal ear skin was floated on medium and cultured. After
3 d, epidermal and dermal sheets were prepared, stained for the indicated markers, and analyzed using a CLM (A). Emigrated cells were harvested,
stained with trypan blue to exclude dead cells and counted (B). Results represent mean  SD of DC/LC per well over six wells. Emigrated cells were
analyzed by flow cytometry for the expression of the indicated markers (C). po0.01 versus control. Scale bars: 20 mm.
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molecules and impairing their allostimulatory activity (Pan-
hans-Gross et al, 2001). Wollenberg et al (2001) have shown
that topical application of tacrolimus reduces the numbers
of inflammatory dendritic epidermal cells in atopic skin
lesions, while the LC population remained essentially
unaffected. In the murine system, topical treatment of
healthy skin with pimecrolimus at therapeutic concentra-
tions reportedly has no gross effect on the number and
phenotype of LC (Meingassner et al, 2003d). In the present
study, we now show that (i) freshly isolated murine LC and
keratinocytes express macrophilin-12 and glucocorticoid
receptors, (ii) CS but not therapeutically effective doses
of pimecrolimus induce LC apoptosis in vivo, (iii) CS, in
contrast to pimecrolimus, alter the maturation and migration
capacity of LC, and (iv) CS but not pimecrolimus markedly
impair the antigen-presenting function of LC.
Belsito et al (1982) reported that after topical application
of CS, some LC exhibit damage ultrastructurally. Aberer
et al (1986) found that after topical or systemic treatment
with CS, LC could no longer be detected in murine skin,
implying that CS cause LC cytotoxicity. We describe now
for the first time that the decrease in LC number upon
topical CS treatment occurs through apoptotic cell death,
as demonstrated by nuclear DNA break and caspase-3
activity in LC. The mechanism(s) leading to CS-induced
apoptosis has yet to be elucidated. We repeatedly found
Figure 5
CS but not pimecrolimus induce apoptosis in LC in situ. (A) BALB/c mice were topically treated with compounds and vehicle, and 72 h later ear
epidermal sheets were subjected to the TUNEL technique and then stained with a PE-conjugated anti-MHC class II MoAb. To induce DNA breaks in
the nucleus (¼positive control; 95% LC), epidermal sheets were incubated with 1500 U per mL DNase I (1 h, 371C) and then subjected to double
labeling. Data analysis and acquisition was performed as described in Materials and Methods. Results are shown as a dot plot. (B) Forty randomly
selected fields per sheet (n¼8 per group) were scanned. Experiments were repeated three times and 960 pictures per group were analyzed.
po0.001 versus control, po0.05 versus control. Scale bars: 20 mm.
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upregulation of CD95 in LC but no enhanced expression of
CD95L in LC or keratinocytes. In addition, the finding that
CS-induced apoptosis was not prevented by a neutralizing
CD95L MoAb indicates that triggering of CD95 by CD95L is
not responsible for cell death. It remains to be seen whether
homotypic ligation of CD95 or other yet unknown ligands
play a role in our experimental system. Furthermore, we also
found TUNELþ keratinocytes and a decreased production
of pro-inflammatory cytokines in EC cultures, indicating that
the low LC yield obtained after CS treatment may not only
be due to a direct apoptotic effect of CS on LC but also to a
loss of mediators produced by basal keratinocytes. This is
supported by our findings that GM-CSF significantly
improved LC viability and restored their function when
added to EC cultures isolated from mice treated with CS
(data not shown). Thus, we conclude that CS deliver a pro-
apoptotic signal for LC via downregulation of pro-inflam-
matory cytokines in keratinocytes. This is supported by data
showing that topically applied GM-CSF partially protects
LC from depletion by a steroid (O’Sullivan et al, 1996). Our
results differ somewhat from the observation of others that
CS have no apoptotic effects on CD34-derived human LC
(Woltman et al, 2002). Species differences, the use of other
types of CS, and different culture conditions could be
responsible for this discrepancy.
As one important element of the skin, LC initiate and
regulate protective immunity in skin in that they recognize
foreign agents, metabolize their proteins into short frag-
ments, and then undergo a process termed maturation as
evidenced by changes of their phenotype and function.
They then traffic to lymph nodes where they activate naı¨ve
antigen-specific T cells, which then return to the skin. In this
study we have investigated whether and how CS and
pimecrolimus interfere with these abilities of LC. We found
that LC from CS-treated mice show a decrease in their
capacity to present a soluble antigen to T cells. A possible
mechanism responsible for the inhibition of T cell responses
is the different expression of molecules involved in T cell
activation. Indeed, we have shown that the expression of
costimulatory molecules, relevant for T cell activation, was
significantly higher on LC derived from vehicle-treated mice
than on those of CS-treated animals. As predicted by
the fact that CS decrease costimulatory molecules, LC-
enriched EC also induced significantly less T cell prolifera-
tion than LC-enriched EC isolated from vehicle-treated
mice. In preliminary experiments we found that the low T
cell response is not only due to the downregulation of
costimulatory molecules on LC by CS but also reflects a
demise in culture of originally viable yet injured LC (data not
shown). In contrast, LC from pimecrolimus-treated mice
compared with LC from vehicle-treated mice in their Ag
uptake, processing/presenting capacity, and their ability to
stimulate naive T cells. Furthermore, our observation that
the numbers of DC/LC collected from pimecrolimus-treated
explants were comparable to those recovered from control
organ cultures, and that pimecrolimus does not influence
the expression of costimulatory molecules of migrating DC/
LC, implies that pimecrolimus inhibits neither LC migration
nor maturation. In line with this are results showing that a
systemic treatment of mice with pimecrolimus effectively
inhibits the elicitation but not the sensitization phase in
murine CHS (Meingassner et al, 2003b). In contrast,
tacrolimus inhibits the sensitization phase in the same
experimental setting. It is thus conceivable that tacrolimus
and pimecrolimus act differently on LC in their ability to
stimulate naive T cells. When we assessed proliferative
responses in the MLR however, LC from tacrolimus-treated
mice were equal in their stimulatory capacity as compared
to LC from pimecrolimus-treated mice (data not shown).
Although the stimulatory capacity of pimecrolimus-treated
LC is similar to the control, we observed differences in the
quality of the T cell response. Whereas IFN-g production was
comparably high in both groups, we monitored enhanced
secretion of IL-4 and IL-10 by T cells primed with LC-
enriched EC from pimecrolimus-treated mice compared
to controls. This finding indicates that LC isolated from
pimecrolimus-treated skin acquire the capacity to skew
T cells into a TH2 direction. In line with our data, Shimizu et al
(2000) have shown that treatment of CD34þ hematopoietic
progenitor cells with tacrolimus can promote the develop-
ment of DC that drive CD4þ T cells toward a TH2 response.
It is well known that patients suffering from atopic
dermatitis are at high risk for certain infections (e.g.
Staphylococcus aureus, Herpes simplex) (Lever et al, 1987;
Bork and Brauninger, 1988). Therefore, it would be
beneficial to have compounds available that act more
selectively than CS and leave the indigenous immune
system of the skin unaltered. In this study, we demonstrated
that short-term treatment of murine skin with pimecrolimus
does not overtly affect the immune function of LC in
contrast to CS. It thus appears that topical pimecrolimus
does not grossly interfere with cutaneous immune surveil-
Figure 6
CS induce caspase-3 activity and upregulate CD95
expression in LC in contrast to pimecrolimus. BALB/c
mice were topically treated with compounds and vehicle,
and 24 (B) and 48 (A) h later EC suspensions were
prepared and analyzed for CD95 expression and caspase
activity by flow cytometry. 104 MHC class IIþ LC were
acquired and antigen expression is shown as a histo-
gram. Data are representative of three experiments.
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lance and thus might have a higher safety profile in the
treatment of atopic dermatitis than CS. Further in vitro and
in vivo studies with human LC are needed to test the validity
of this assumption.
Materials and Methods
Animals Female BALB/c (H-2d) and male C57BL/6 (H-2b) mice
(11–13-wk-old) were obtained from Charles River Wiga (Sulzfeld,
Germany) and maintained conventionally under standard animal
house conditions with standard laboratory chow (SNIFF R/M-H diet
for mice and rats, Soest, Germany) and drinking water, given ad
libitum. The animals were used according to an approved protocol
compliant with Helsinki guidelines under licence #MA4008/
99 (Magistratsabteilung 58, Amt der Wiener Landesregierung).
Compounds and application scheme The test compounds were
dissolved in ethanol and applied at their clinically used concentra-
tions: 1% HC, 0.05% CL (both from Sigma, St Louis, Missouri), 1%
pimecrolimus ((Elidel, SDZ ASM 981), Novartis Pharma AG, Basel,
Switzerland). The treatment comprised two applications to both
sides of the auricles (20 mL per ear) and tail (150 mL), twice on 1 d
(8 h in between). Control animals were treated similarly with the
solvent (ethanol) alone. For exact dosing, the application of the
compounds was performed under nembutal anesthesia.
Reagents The culture medium RPMI 1640 was supplemented
with 10% heat-inactivated FCS (PAA Laboratories GmbH, Linz,
Austria), 25 mM HEPES, 10 mg per mL gentamycin, 2 mM
L-glutamine, 0.1 mM non-essential amino acids, 1 mM sodium
pyruvate, 50 mM 2-ME, and 1  antibiotic–antimycotic solution (all
from Gibco Life Technologies, Grand Island, New York). The MoAb
500A2 (anti-CD3), GK1.5 (anti-CD4), 53-6.72 (anti-CD8), M1/70
(anti-CD11b), 2.4G2 (anti-CD16/CD32) M1/69 and J11d (anti-
CD24), 3C7 and 7D4 (anti-CD25), 3/23, HM40-3 (anti-CD40), IM7
(anti-CD44), 30-F11 (anti-CD45), 3E2 (anti-CD54), 16-10A1 (anti-
CD80), GL1 (anti-CD86), Jo2 (anti-CD95, Fas), MFL3 (anti-CD95L,
FasL) M5/114.15.2 (anti-I-Ab,d,q & I-Ed,k) (all from PharMingen, San
Diego, California), 8 (anti-macrophilin-12, Affinity Bioreagents,
Golden, Colorado), BuGR2 (anti-glucorticoid receptor, Transduc-
tion Laboratories, Lexington, Kentucky), NLDC-145 (anti-CD205,
Serotec, Oxford, UK) were used unlabeled, FITC- or PE-con-
jugated. Hybridomas F4/80 (anti-macrophage, HB 198), RA3-3A1/
6.1 (anti-CD45R/B220, TIB 146) were obtained from the American
Type Culture Collection (Manassas, Virginia). Second-step re-
agents were FITC-F(ab0)2 goat anti-rabbit IgG (Zymed, South San
Francisco, California) and FITC-F(ab0)2 goat anti-mouse IgMþ IgG
(Bio Research, An der Grub, Austria). Irrelevant, isotype-matched
MoAb were applied as negative control. FITC-OVA and hen egg
lysozyme (HEL) were purchased from Molecular Probes (Eugene,
Oregon) and Sigma, respectively.
Epidermal/dermal sheets and cell suspensions Epidermal and
dermal sheets were prepared as described (Payer et al, 1991) and
then subjected to immunofluorescence staining. Immunostained
sheets were analyzed using a confocal laser scanning microscope
(CLM 510, Carl Zeiss, Jena, Germany). Epidermal cell (EC) and
dermal cell suspensions from ears and tails were prepared (Elbe-
Bu¨rger et al, 2002) and used for flow cytometry analyses, antigen-
processing assays, and EC cultures (1.5  106 cells per mL) at
371C. After 48 h, non-adherent EC were harvested and dead cells
were largely eliminated by density gradient centrifugation (Lym-
pholyte-M, Cedarlane Laboratories, Hornby, Ontario, Canada). The
resulting cell suspensions were either analyzed by flow cytometry
or utilized for functional studies.
CHS responses BALB/c mice (n¼ 8 per group) were sensitized on
the shaved abdomen with 50 mL of oxazolone (2% in acetone;
Sigma) and challenged with 10 mL of 0.5% oxazolone on the inner
surface of the right ear on day 8. The unchallenged left ears served
as normal controls. Dermatitis was evaluated from the difference in
auricular weight (taken as a measure of inflammatory swelling) 24 h
after challenge. Pimecrolimus (1%) (10 mL per ear, dissolved in
ethanol) was applied topically to the challenge site 0.5 and 8.5 h
after the challenge. Control animals were treated with ethanol
Figure 7
Comparison of the cytokine production of EC treated with
compounds in vivo. BALB/c mice were topically applied with
compounds and vehicle, and 48 h later EC suspensions were prepared
and cultured for 72 h. Supernatants were screened for the presence of
the indicated cytokines by ELISA. Data (n¼ 4) are expressed in pg per
mL as mean concentration  SD of triplicates. po0.001 versus
control, po0.01 versus control, po0.05 versus control.
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alone. The anti-inflammatory activity of pimecrolimus was calcu-
lated as the percentage inhibition of auricular weight increase
relative to mice treated with vehicle alone.
Flow cytometry analysis For two-color analysis, cells (5  105
per sample) were resuspended in cold PBS/1% FCS/0.1% NaN3
and serially incubated with FITC-conjugated MoAb directed
against selected mouse antigens and PE-conjugated anti-CD45
MoAb (30 min, 41C). Specificity of staining was confirmed using
isotype-matched control MoAb. Fluorescence was measured
using a FACScan flow cytometer, and data were analyzed with
Cell Quest software (both from Becton Dickinson, San Jose, CA).
Dead cells were excluded by 7-amino-actinomycin D (Sigma)
uptake. For the detection of cytoplasmatic macrophilin-12, cells
were first fixed and permeabilized with Cytofix/Cytoperm solution
(Pharmingen) for 20 min at 41C, washed and then incubated with
the non-conjugated first-step Ab in PBS/0.1% Saponin (30 min,
41C), washed, exposed to an appropriately diluted FITC-
conjugated second-step reagent, and counterstained with a PE-
labeled M5/114 MoAb (30 min, 41C). To identify the glucocorticoid
receptor (Wiegers et al, 2001), cells were stained with the PE-
labeled M5/114 MoAb (30 min, 41C), washed, fixed in 0.5%
paraformaldehyde for 30 min, and permeabilized with 0.05% Triton
X-100 in 0.1% sodium citrate (5 min, 41C). After three additional
washing steps, cells were stained for 1 h with non-conjugated anti-
glucocorticoid receptor MoAb, washed, and then incubated for
30 min with an appropriate FITC-F(ab0)2 second-step antibody. To
evaluate caspase activity in LC, a CaspGLOW fluorescein active
caspase-3 staining kit was purchased from BioVision (Research,
Mountain View, California) and used according to the manufac-
turer’s instructions. Briefly, cells (5  105) were incubated for 1 h
with caspase-3 inhibitor (FITC-conjugated DEVD-FMK), which
binds irreversibly to active caspase-3 at 371C. Then cells were
washed three times, counterstained with PE-labeled MoAb M5/115
MoAb, and analyzed by flow cytometry. CD95L expression on LC
was assessed essentially as described (Shibaki and Katz, 2001).
Auricular skin cultures Organ cultures of auricular skin were
performed essentially as described (Larsen et al, 1990; Ortner et al,
1996). Briefly, vehicle- and compound-treated ears were rinsed in
70% ethanol, and split and dorsal ear halves were floated dermal-
side down on 2 mL culture medium for 3 d. Non-adherent
migratory cells were collected from the bottom of the wells, and
cell numbers and viability (trypan blue exclusion) were assessed
under a light microscope. FACS analysis of the migrated cells and
stainings of epidermal and dermal sheets were performed as
described above.
Assessment of LC apoptosis by TUNEL To detect DNA breaks
in situ, auricular epidermal sheets were cut into small pieces (  6
mm2), fixed with 4% paraformaldehyde (30 min, room tempera-
ture), and then washed three times in PBS. Sheets were
permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for
1 h, extensively washed, and afterwards subjected to TUNEL
labeling according to the manufacturer’s instructions (Roche
Molecular Biochemicals, Mannheim, Germany). To identify LC,
epidermal sheets were counterstained with the PE-labeled MoAb
M5/114 (1 h, 371C). As a positive control, epidermal sheets were
first incubated with 1500 U per mL DNase I (1 h, 371C) to induce
DNA breaks in the nucleus, and were then subjected to TUNEL/
MHC class II double staining. Immunostained sheets were
analyzed using a confocal laser scanning microscope.
Table II. Addition of GM-CSF to EC suspensions prepared from CS-treated mice greatly improves LC viabilitya
Treatment Cytokines Numbers of viable EC after 2 d of culture Numbers of viable LC after 2 d of culture
Control — 1.2  106 2.2  105 (100%)
Clobetasol — 2.1  106 0.5  105 (25%)
Control GM-CSF 0.9  106 2.3  105 (104%)
Clobetasol GM-CSF 2.7  106 1.8  105 (86%)
aBALB/c mice were treated twice on 1 d on both sides of the ears with a 20 mL ethanolic solution of clobetasol propionate (0.05%). Controls were
treated with ethanol (vehicle) alone. Forty-eight hours after the last application, EC suspensions were prepared from auricular skin, adjusted to equal
numbers of LC, as determined by flow cytometry, and cultured in normal cell culture medium for 2 d in the presence or absence of GM-CSF (200 U per
mL). Cells were counted under a light microscope and dead cells were excluded by trypan blue uptake. Data are representative of at least two
experiments.
Figure 8
Pimecrolimus enhances the endocytic activity but not the antigen-
processing capacity of LC. BALB/c mice were topically treated with
pimecrolimus, CS, and vehicle. Forty-eight hours later, endocytosis and
the antigen-processing capacity of LC was tested. (A) Endocytosis was
evaluated as the uptake of FITC-OVA (1 mg per mL) by MHC class IIþ
LC at the indicated time points and measured by flow cytometry.
Results are presented as the MFI of internalized OVA and are
representative of three independent experiments. (B, C) EC suspen-
sions were cultured in the presence of HEL (1 mg per mL) for 24 h. The
non-adherent cells were harvested, washed three times, and LC-
enriched EC (10%–20% MHC class IIþ cells in all groups) (B) or highly
purified LC (C, LC purity: vehicle and pimecrolimus  90%, CL
 70%) were cocultured at 103 LC per well with 1H11.3 hybridoma
cells (105 per well) for 24 h. Supernatants were harvested and IL-2
production was determined by ELISA. Hybridoma cells failed to
produce IL-2 when cultured with unpulsed LC (data not shown). Data
are representative of at least two experiments. po0.001 versus
control, po0.01 versus control, po0.05 versus control.
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Quantiﬁcation of apoptotic (TUNELþ ) cells Data acquisition
and image cytometry was performed using an automated
fluorescence–confocal laser scanning microscope and the analysis
software TissueQuest, (Vienna, Austria) which permitted recogni-
tion of individual cells by a specific identification strategy (Steiner
et al, 2000). In brief, 40 randomly selected fields per sheet (n¼ 8
per group) under  40 object lenses (one field: 0.2375 mm2) were
scanned. Target cells were labeled as described above. Specificity
of the staining procedure and accuracy of instrument settings were
crosschecked by isotype-matched negative controls. Cellular
sub-populations were defined and the thresholds for statistical
evaluation were set according to the negative controls.
Assessment of cytokine production in EC cultures EC were
prepared and cultured as described above. After 72 h supernatants
were harvested and stored at 201C until use. Cytokine concentra-
tions were determined by ELISA according to the manufacturer’s
instructions for GM-CSF, IL-1a (Endogen, Woburn, Maasachusetts),
and TNF-a (Genzyme, Cambridge, Massachussetts).
Endocytosis assay Freshly prepared EC were first stained with
PE-labeled M5/114 (30 min, 41C), washed, incubated with FITC-
OVA at 371C, and analyzed by flow cytometry. FITC-OVA uptake
was quantified as MFI. Non-specific FITC signal was assessed by
incubating cells with FITC-OVA at 41C. For the time course of
uptake, cells were incubated with 2 mg per mL FITC-OVA (1  106
cells) for 0–90 min.
Ag-processing assay The processing activity of LC after topical
treatment was measured using the HEL-specific, MHC class II
(I-Ed)-restricted T cell hybridoma 1H11.3 (Koch et al, 1995). The
activation of the hybridoma was determined by measuring IL-2
production by ELISA (Endogen). Briefly, freshly prepared EC from
the different groups were cultured either with or without HEL (1 mg
per mL) for 24 h. Thereafter, non-adherent cells were washed three
times, and LC were enriched by density gradient centrifugation and
adjusted to equal numbers of LC as determined by flow cytometry.
In certain experiments, LC were highly purified using the
mismatched panning technique (Koch et al, 1992). HEL-pulsed
and, for control purposes, unpulsed LC-enriched EC or purified LC
of each group were cultured either with or without hybridoma cells
(105 per well) in 96- well flat-bottom microtiter plates. Supernatants
were harvested after 24 h and stored at 201C until use.
Figure9
CS but not pimecrolimus impair LC maturation and
hamper their stimulatory capacity. BALB/c mice were
treated twice on 1 d on both sides of the ears and the tail
with the indicated compounds and vehicle alone. Forty-
eight hours after the last application, EC suspensions
were prepared from auricular and tail skin and cultured.
After 2 days, non-adherent EC were harvested and tested
for phenotype and function. (A) 104 cells per sample were
acquired and MFI (mean  SD (n¼3)) expression of the
indicated markers on LC is shown. (B) Equal numbers of
viable LC (103 per well) were cocultured with naı¨ve,
allogeneic CD4þ or CD8þ T cells in 96-well round-
bottom microtiter plates. Proliferative responses were
determined on days 3–6 of culture. Error bars represent
SD of triplicate cultures. LC, CD4þ , and CD8þ T cells did
not proliferate when cultured with medium alone. Data
shown are representative of three experiments. (C) To
determine the cytokine profile, CD4þ T cells were primed
in the MLR by LC-enriched EC from vehicle and
pimecrolimus-treated mice, expanded with IL-2, and
restimulated with irradiated APC as described in Materi-
als and Methods. Cytokine production was measured
by ELISA. APC alone failed to produce any cytokines.
Data shown are representative of two experiments.
po0.001 versus control, po0.01 versus control,
po0.05 versus control.
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MLR CD4þ and CD8þ T cells were prepared from mesenteric
lymph nodes of C57BL/6 mice essentially as described (Elbe-
Bu¨rger et al, 2002). EC suspensions of different groups were
prepared as described above and cultured for 48 h. Non-adherent
cells were harvested and dead cells were largely eliminated by
density gradient centrifugation. Adjusted numbers of LC (103 per
well) were cultured alone or cocultured with allogeneic CD4þ and
CD8þ T cells (105 per well) in 96-well round-bottom culture plates
(Costar, Acton, MA). At the indicated time points, cells were pulsed
with (3H)-TdR (37 KBq per well) for 8 h and incorporation of the
radionucleotide was measured by b-scintillation spectroscopy
(Wallac Oy, Turku, Finland). Data are expressed as mean cpm 
SD of triplicate. The responder and stimulator cells alone never
exceeded 300 and 450 cpm, respectively. To determine the
cytokine profile, CD4þ T cells were primed in an allogeneic MLR
(as described above). After 4 d, T cells were washed, resuspended
in medium containing IL-2 (50 U per ml; generously provided by
Dr E. Liehl, Novartis Institute for Biomedical Research, Vienna,
Austria), and expanded for 7 d. On day 11, T cells were washed
twice and 105 T cells were restimulated with 105 irradiated APC (15
Gy; T cell-depleted spleen cells). Supernatants were harvested
after 48 h and cytokine concentrations were determined by ELISA
according to the manufacturer’s instructions for IFN-g, IL-4, and IL-
10 (Endogen).
Statistical analysis One-way analysis of variance (ANOVA) was
used to evaluate statistically significant differences (po0.05)
between test and control groups.
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